{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:11:35Z","timestamp":1790399495837,"version":"4.1.0"},"reference-count":111,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T00:00:00Z","timestamp":1647561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007076","name":"Italian Association for Cancer Research","doi-asserted-by":"publisher","award":["IG-25024"],"award-info":[{"award-number":["IG-25024"]}],"id":[{"id":"10.13039\/501100007076","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ricerca per Credere nella Vita RCV odv","award":["grant to LT"],"award-info":[{"award-number":["grant to LT"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Monoclonal gammopathy and peripheral neuropathy are common diseases of elderly patients, and almost 10% of patients with neuropathy of unknown cause have paraprotein. However, growing evidence suggests that several hematological malignancies synthesize and release monoclonal proteins that damage the peripheral nervous system through different mechanisms. The spectrum of the disease varies from mild to rapidly progressive symptoms, sometimes affecting not only sensory nerve fibers, but also motor and autonomic fibers. Therefore, a multidisciplinary approach, mainly between hematologists and neurologists, is recommended in order to establish the correct diagnosis of monoclonal gammopathy of neurological significance and to tailor therapy based on specific genetic mutations. In this review, we summarize the spectrum of monoclonal gammopathies of neurological significance, their distinctive clinical and neurophysiological phenotypes, the most relevant pathophysiological events and new therapeutic approaches.<\/jats:p>","DOI":"10.3390\/cancers14061562","type":"journal-article","created":{"date-parts":[[2022,3,20]],"date-time":"2022-03-20T21:25:00Z","timestamp":1647811500000},"page":"1562","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["From Biology to Treatment of Monoclonal Gammopathies of Neurological Significance"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0271-7200","authenticated-orcid":false,"given":"Andrea","family":"Visentin","sequence":"first","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pravato","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4590-2548","authenticated-orcid":false,"given":"Francesca","family":"Castellani","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neurosciences, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Campagnolo","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neurosciences, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Angotzi","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Adele","family":"Cavarretta","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cellini","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Ruocco","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Salvalaggio","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neurosciences, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, 20162 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1222-6149","authenticated-orcid":false,"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[{"name":"Hematology and Clinical Immunology Unit, Department of Medicine, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8035-0200","authenticated-orcid":false,"given":"Chiara","family":"Briani","sequence":"additional","affiliation":[{"name":"Neurology Unit, Department of Neurosciences, University of Padova, 35128 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jns.12295","article-title":"Peripheral nervous system involvement in lymphomas","volume":"24","author":"Briani","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/hon.2694","article-title":"New responsibilities for aged kinases in B-lymphomas","volume":"38","author":"Piazza","year":"2020","journal-title":"Hematol. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41568-021-00407-4","article-title":"The manipulation of apoptosis for cancer therapy using BH3-mimetic drugs","volume":"22","author":"Diepstraten","year":"2022","journal-title":"Nat. Rev. Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.3324\/haematol.2019.227272","article-title":"MYD88 in the driver\u2019s seat of B-cell lymphomagenesis: From molecular mechanisms to clinical implications","volume":"104","author":"Schrader","year":"2019","journal-title":"Haematologica"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","article-title":"MYD88 L265P Mutation in Lymphoid Malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/nature09121","article-title":"Helical assembly in the MyD88\u2013IRAK4-IRAK2 complex in TLR\/IL-1R signalling","volume":"465","author":"Lin","year":"2010","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Severin, F., Frezzato, F., Visentin, A., Martini, V., Trimarco, V., Carraro, S., Tibaldi, E., Brunati, A.M., Piazza, F., and Semenzato, G. (2019). In Chronic Lymphocytic Leukemia the JAK2\/STAT3 Pathway Is Constitutively Activated and Its Inhibition Leads to CLL Cell Death Unaffected by the Protective Bone Marrow Microenvironment. Cancers, 11.","DOI":"10.3390\/cancers11121939"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1002\/ijc.32383","article-title":"HSP70\/HSF1 axis, regulated via a PI3K\/AKT pathway, is a druggable target in chronic lymphocytic leukemia","volume":"145","author":"Frezzato","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/bjh.14642","article-title":"Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells","volume":"178","author":"Martini","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.hoc.2018.05.003","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia","volume":"32","author":"Treon","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Nakamura, A., Ohwada, C., Takeuchi, M., Takeda, Y., Tsukamoto, S., Mimura, N., Nagisa, O.-H., Sugita, Y., Tanaka, H., and Wakita, H. (2019). Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenstr\u00f6m\u2019s macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0221941"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1038\/s41375-018-0197-7","article-title":"Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies","volume":"32","author":"Bagratuni","year":"2018","journal-title":"Leukemia"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/practneurol-2020-002837","article-title":"Paraproteinaemic neuropathy: MGUS and beyond","volume":"21","author":"Carroll","year":"2021","journal-title":"Pract. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.31.11.1480","article-title":"Prevalence of monoclonal protein in peripheral neuropathy","volume":"31","author":"Kelly","year":"1981","journal-title":"Neurology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1212\/WNL.0000000000003293","article-title":"Prevalence of polyneuropathy in the general middle-aged and elderly population","volume":"87","author":"Hanewinckel","year":"2016","journal-title":"Neurology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/bjh.16086","article-title":"A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD 88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenstr\u00f6m macroglobulinaemia or other lymphoproliferative disorders","volume":"187","author":"Varettoni","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"577725","DOI":"10.1016\/j.jneuroim.2021.577725","article-title":"Anti-MAG neuropathy: From biology to clinical management","volume":"361","author":"Steck","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/WCO.0000000000000975","article-title":"Antibody testing in neuropathy associated with anti-Myelin-Associated Glycoprotein antibodies: Where we are after 40 years","volume":"34","author":"Latov","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/ene.13387","article-title":"Anti-sulfatide\/galactocerebroside antibodies in immunoglobulin M paraproteinemic neuropathies","volume":"24","author":"Boso","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1212\/WNL.0b013e3181ccc6b9","article-title":"Prognosis of polyneuropathy due to IgM monoclonal gammopathy: A prospective cohort study","volume":"74","author":"Niermeijer","year":"2010","journal-title":"Neurology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1468-1331.2010.03312.x","article-title":"Non-anti-MAG DADS neuropathy as a variant of CIDP: Clinical, electrophysiological, laboratory features and response to treatment in 10 cases","volume":"18","author":"LaRue","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.clml.2015.11.004","article-title":"Bing Neel Syndrome in a Previously Untreated Patient with Waldenstr\u00f6m\u2019s Macroglobulinemia: Contribution of MYD88 L265P Mutation on Cerebrospinal Fluid","volume":"16","author":"Frustaci","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/blood-2018-10-879593","article-title":"Ibrutinib for the treatment of Bing-Neel syndrome: A multicenter study","volume":"133","author":"Castillo","year":"2019","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2015.02.009","article-title":"Polyneuropathy with anti-sulfatide and anti-MAG antibodies: Clinical, neurophysiological, pathological features and response to treatment","volume":"281","author":"Campagnolo","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1182\/blood.2020007092","article-title":"CANOMAD: A neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies","volume":"136","author":"Bouhour","year":"2020","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1182\/blood-2016-09-719773","article-title":"How I treat cryoglobulinemia","volume":"129","author":"Muchtar","year":"2017","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrneurol.2014.117","article-title":"Diagnosis and treatment of chronic acquired demyelinating polyneuropathies","volume":"10","author":"Latov","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/jns.12342","article-title":"Limitations in daily activities and general perception of quality of life: Long term follow-up in patients with anti-myelin-glycoprotein antibody polyneuropathy","volume":"24","author":"Campagnolo","year":"2019","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_32","first-page":"CD002827","article-title":"Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies","volume":"2016","author":"Lunn","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1002\/ana.21577","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy","volume":"65","author":"Dalakas","year":"2009","journal-title":"Ann. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1212\/WNL.0b013e318296e92b","article-title":"Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy","volume":"80","author":"Viala","year":"2013","journal-title":"Neurology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/jnnp-2017-315736","article-title":"IgM MGUS and Waldenstrom-associated anti-MAG neuropathies display similar response to rituximab therapy","volume":"88","author":"Campagnolo","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e155","DOI":"10.3324\/haematol.2013.087213","article-title":"Immunotherapy-based regimen in anti-MAG neuropathy: Results in 45 patients","volume":"98","author":"Hospital","year":"2013","journal-title":"Haematologica"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1529-8027.2011.00343.x","article-title":"Long-term response to rituximab and fludarabine combination in IgM anti-myelin-associated glycoprotein neuropathy","volume":"16","author":"Gruson","year":"2011","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"116777","DOI":"10.1016\/j.jns.2020.116777","article-title":"Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy","volume":"413","author":"Massa","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e460","DOI":"10.1212\/NXI.0000000000000460","article-title":"Obinutuzumab, a potent anti-B-cell agent, for rituximab-unresponsive IgM anti-MAG neuropathy","volume":"5","author":"Rakocevic","year":"2018","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ene.13838","article-title":"Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy","volume":"26","author":"Briani","year":"2019","journal-title":"Eur. J. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e720","DOI":"10.1212\/NXI.0000000000000720","article-title":"The Bruton tyrosine kinase inhibitor ibrutinib improves anti-MAG antibody polyneuropathy","volume":"7","author":"Castellani","year":"2020","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib monotherapy in patients with Waldenstr\u00f6m macroglobulinemia: A single-arm, multicentre, phase 2 study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: The ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1182\/bloodadvances.2021005621","article-title":"Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies","volume":"6","author":"Tam","year":"2022","journal-title":"Blood Adv."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: A substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jama.2020.5493","article-title":"Systemic Amyloidosis Recognition, Prognosis, and Therapy: A Systematic Review","volume":"324","author":"Gertz","year":"2020","journal-title":"JAMA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.beha.2016.08.013","article-title":"Monoclonal IgM-related AL amyloidosis","volume":"29","author":"Milani","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Briani, C., Ferrari, S., Campagnolo, M., Tagliapietra, M., Castellani, F., Salvalaggio, A., Mariotto, S., Visentin, A., and Cavallaro, T. (2021). Mechanisms of Nerve Damage in Neuropathies Associated with Hematological Diseases: Lesson from Nerve Biopsies. Brain Sci., 11.","DOI":"10.3390\/brainsci11020132"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jns.12381","article-title":"Acquired and inherited amyloidosis: Knowledge driving patients\u2019 care","volume":"25","author":"Obici","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Manni, S., Brancalion, A., Mandato, E., Tubi, L.Q., Colpo, A., Pizzi, M., Cappellesso, R., Zaffino, F., Di Maggio, S.A., and Cabrelle, A. (2013). Protein Kinase CK2 Inhibition Down Modulates the NF-\u03baB and STAT3 Survival Pathways, Enhances the Cellular Proteotoxic Stress and Synergistically Boosts the Cytotoxic Effect of Bortezomib on Multiple Myeloma and Mantle Cell Lymphoma Cells. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0075280"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/ajh.26240","article-title":"POEMS syndrome: 2021 Update on diagnosis, risk-stratification, and management","volume":"96","author":"Dispenzieri","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Briani, C., Campagnolo, M., Luigetti, M., Lessi, F., and Adami, F. (2020). POEMS syndrome. Dysimmune Neuropathies, Academic Press.","DOI":"10.1016\/B978-0-12-814572-2.00006-6"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/mus.21872","article-title":"Vascular endothelial growth factor helps differentiate neuropathies in rare plasma cell dyscrasias","volume":"43","author":"Briani","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jneuroim.2014.09.021","article-title":"Pentraxin-3 and VEGF in POEMS syndrome: A 2-year longitudinal study","volume":"277","author":"Briani","year":"2014","journal-title":"J. Neuroimmunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1093\/brain\/awh519","article-title":"Polyneuropathy in POEMS syndrome: Role of angiogenic factors in the pathogenesis","volume":"128","author":"Scarlato","year":"2005","journal-title":"Brain"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1038\/s41375-018-0348-x","article-title":"Genetic and transcriptional landscape of plasma cells in POEMS syndrome","volume":"33","author":"Nagao","year":"2019","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s12185-020-02829-6","article-title":"Molecular basis of clonal evolution in multiple myeloma","volume":"111","author":"Furukawa","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1136\/jnnp-2011-300047","article-title":"Pachymeningeal involvement in POEMS syndrome: MRI and histopathological study","volume":"83","author":"Briani","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s00415-019-09233-z","article-title":"Frequent central nervous system, pachymeningeal and plexus MRI changes in POEMS syndrome","volume":"266","author":"Ziff","year":"2019","journal-title":"J. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ajh.23148","article-title":"Pachymeningeal involvement in POEMS syndrome: Dramatic cerebral MRI improvement after lenalidomide therapy","volume":"87","author":"Briani","year":"2012","journal-title":"Am. J. Hematol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/jnen\/nlaa021","article-title":"Skin and Nerve Neovascularization in POEMS Syndrome: Insights from a Small Cohort","volume":"79","author":"Guibert","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00415-018-9068-4","article-title":"An update on the diagnosis and management of the polyneuropathy of POEMS syndrome","volume":"266","author":"Cerri","year":"2019","journal-title":"J. Neurol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1212\/WNL.0000000000001565","article-title":"Polyneuropathy improvement following autologous stem cell transplantation for POEMS syndrome","volume":"84","author":"Karam","year":"2015","journal-title":"Neurology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.bbmt.2019.08.011","article-title":"Peripheral Blood Hemopoietic Stem Cell Mobilization Regimens in POEMS Syndrome: A Retrospective Study at 2 Hematologic Italian Centers","volume":"25","author":"Autore","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-019-0391-2","article-title":"What is the best first-line treatment for POEMS syndrome: Autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone?","volume":"33","author":"Zhao","year":"2019","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1212\/01.wnl.0000323811.42080.a4","article-title":"Neurologic improvement after peripheral blood stem cell transplantation in POEMS syndrome","volume":"71","author":"Kuwabara","year":"2008","journal-title":"Neurology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hon.2478","article-title":"Autologous peripheral blood stem cell transplantation and the role of lenalidomide in patients affected by poems syndrome","volume":"36","author":"Autore","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/bjh.14966","article-title":"Lenalidomide and dexamethasone in patients with POEMS syndrome: Results of a prospective, open-label trial","volume":"179","author":"Nozza","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000343681","article-title":"Effective Induction Therapy with Subcutaneous Administration of Bortezomib for Newly Diagnosed POEMS Syndrome: A Case Report and a Review of the Literature","volume":"129","author":"Zeng","year":"2013","journal-title":"Acta Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1080\/10428194.2018.1564048","article-title":"Bortezomib-based regimens in patients with POEMS syndrome: A case series in newly diagnosed and relapsed patients","volume":"60","author":"Riva","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.mayocp.2018.02.001","article-title":"Daratumumab for POEMS Syndrome","volume":"93","author":"Khan","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13045-018-0672-7","article-title":"Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: Case report on POEMS syndrome and multiple myeloma","volume":"11","author":"Xu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.hoc.2017.09.008","article-title":"Treatment of Idiopathic Castleman Disease","volume":"32","author":"Greenway","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/S2352-3026(16)00006-5","article-title":"Idiopathic multicentric Castleman\u2019s disease: A systematic literature review","volume":"3","author":"Liu","year":"2016","journal-title":"Lancet Haematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1212\/WNL.0000000000003405","article-title":"Clinical spectrum of Castleman disease-associated neuropathy","volume":"87","author":"Naddaf","year":"2016","journal-title":"Neurology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","article-title":"Siltuximab for multicentric Castleman\u2019s disease: A randomised, double-blind, placebo-controlled trial","volume":"15","author":"Wong","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1080\/14397595.2019.1704983","article-title":"Clinicopathologic characteristics of 342 patients with multicentric Castleman disease in Japan","volume":"30","author":"Murakami","year":"2020","journal-title":"Mod. Rheumatol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.clml.2015.06.001","article-title":"Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients with Chronic Lymphocytic Leukemia","volume":"15","author":"Visentin","year":"2015","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdy021","article-title":"Genetic landscape of ultra-stable chronic lymphocytic leukemia patients","volume":"29","author":"Raponi","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.clml.2019.03.002","article-title":"Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments","volume":"19","author":"Visentin","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/s41416-019-0502-x","article-title":"The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia","volume":"121","author":"Visentin","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Visentin, A., Bonaldi, L., Rigolin, G.M., Mauro, F.R., Martines, A., Frezzato, F., Pravato, S., Gargarella, L.R., Bardi, M.A., and Cavallari, M. (2021). The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. Haematologica.","DOI":"10.3324\/haematol.2021.278304"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/17474086.2018.1495557","article-title":"Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia","volume":"11","author":"Mauro","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Visentin, A., Mauro, F.R., Cibien, F., Vitale, C., Reda, G., Fresa, A., Ciolli, S., Pietrasanta, D., Marchetti, M., and Murru, R. (2021). Continuous treatment with Ibrutinib in 100 untreated patients with TP 53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. Am. J. Hematol., 1\u20135.","DOI":"10.1002\/ajh.26437"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/bjh.16975","article-title":"Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia","volume":"190","author":"Corbingi","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e140","DOI":"10.3324\/haematol.2016.153064","article-title":"Peripheral neuropathies in chronic lymphocytic leukemia: A single center experience on 816 patients","volume":"102","author":"Briani","year":"2017","journal-title":"Haematologica"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00277-016-2852-2","article-title":"Primary neurolymphomatosis as clinical onset of chronic lymphocytic leukemia","volume":"96","author":"Briani","year":"2016","journal-title":"Ann. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hon.2480","article-title":"Idelalisib plus rituximab is effective in systemic AL amyloidosis secondary to chronic lymphocytic leukaemia","volume":"36","author":"Visentin","year":"2018","journal-title":"Hematol. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/jns.12455","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force\u2014Second revision","volume":"26","author":"Doorn","year":"2021","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/hon.2655","article-title":"A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia","volume":"37","author":"Visentin","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1093\/ajcp\/83.2.244","article-title":"Malignant Angioendotheliomatosis: An Angiotropic Lymphoma?","volume":"83","author":"Wrotnowski","year":"1985","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","article-title":"Intravascular large B-cell lymphoma: A chameleon with multiple faces and many masks","volume":"132","author":"Ponzoni","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000334130","article-title":"Intravascular Lymphoma Mimicking Cerebral Stroke: Report of Two Cases","volume":"3","author":"Hundsberger","year":"2011","journal-title":"Case Rep. Neurol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"Schrader","year":"2018","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/mus.21648","article-title":"Disseminated intravascular large-cell lymphoma with initial presentation mimicking Guillain-Barre syndrome","volume":"42","author":"Jiang","year":"2010","journal-title":"Muscle Nerve"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/CND.0b013e318262ab5c","article-title":"Isolated Mononeuropathy Multiplex\u2014A Rare Manifestation of Intravascular Large B-Cell Lymphoma","volume":"14","author":"Lynch","year":"2012","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2169\/internalmedicine.3228-19","article-title":"Demyelinating Neuropathy Due to Intravascular Large B-cell Lymphoma","volume":"59","author":"Fukami","year":"2020","journal-title":"Intern. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_104","first-page":"289","article-title":"Neurolymphomatose p\u00e9riph\u00e9rique humaine","volume":"42","author":"Lhermitte","year":"1934","journal-title":"Presse Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1215\/15228517-5-2-104","article-title":"Neurolymphomatosis","volume":"5","author":"Baehring","year":"2003","journal-title":"Neuro Oncol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/jns.12401","article-title":"Neurolymphomatosis, a rare manifestation of peripheral nerve involvement in lymphomas: Suggestive features and diagnostic challenges","volume":"25","author":"Campagnolo","year":"2020","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1529-8027.2001.01018.x","article-title":"Neurolymphomatosis associated with muscle and cerebral involvement caused by natural killer cell lymphoma: A case report and review of literature","volume":"6","author":"Odabasi","year":"2001","journal-title":"J. Peripher. Nerv. Syst."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1093\/brain\/awt193","article-title":"Clinicopathological features of neuropathy associated with lymphoma","volume":"136","author":"Tomita","year":"2013","journal-title":"Brain"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1212\/WNL.46.4.1191","article-title":"Neurolymphomatosis","volume":"46","author":"Gordon","year":"1996","journal-title":"Neurology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1212\/WNL.45.7.1403","article-title":"Neurolymphomatosis of the median nerve","volume":"45","author":"Beun","year":"1995","journal-title":"Neurology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1212\/WNL.57.4.740","article-title":"Neurolymphomatosis of the lumbar plexus: High-resolution MR neurography findings","volume":"57","author":"Moore","year":"2001","journal-title":"Neurology"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1562\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:39:07Z","timestamp":1760135947000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/6\/1562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,18]]},"references-count":111,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cancers14061562"],"URL":"https:\/\/doi.org\/10.3390\/cancers14061562","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.742302026.793595041","asserted-by":"object"}]},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,18]]}}}